ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Health Technology

SanBio Co., Ltd.

Business Summary

SanBio Co., Ltd. engages in the development, production and sale of regenerative cells medicines. It provides regenerative therapies for neurological disorders that include stroke, traumatic brain injury, eye diseases, and Parkinson's disease. The company was founded on February 27, 2013 and is headquartered in Tokyo, Japan.

Financial Highlights

Jan 2020 JPYUSD
Revenue447.22M4.10M
Gross Profit----
Operating income-5,486.06M-50.31M
Income before tax-5,156.50M-47.28M
Net income-5,157.71M-47.30M
EBITDA-5,446.43M-49.94M
Diluted EPS-100.90-0.92
Dividends Per Share00
Total Assets15,605.41M143.98M
Total liabilities4,675.23M43.13M
Total equity10,930.18M100.84M
Operating cash flow-5,728.82M-52.53M
Currency in JPYCurrency in USD

Historical Data

 Jan 2016Jan 2017Jan 2018Jan 2019Jan 2020
Revenue 1,174.64M 949.54M 490.50M 741.61M 447.22M
Gross Profit -- 905.61M 436.84M -- --
Operating income -1,125.24M -1,932.22M -4,378.38M -3,733.92M -5,486.06M
Income before tax -1,172.40M -2,166.21M -3,939.11M -2,919.35M -5,156.50M
Net income -988.39M -1,835.29M -3,940.32M -2,920.56M -5,157.71M
EBITDA -1,111.10M -1,905.47M -4,324.71M -3,697.05M -5,446.43M
Diluted EPS -22.67 -40.88 -86.85 -60.17 -100.90
Dividends Per Share 0 0 0 -- 0
Total Assets 8,271.01M 6,292.41M 5,193.55M 13,975.97M 15,605.41M
Total liabilities 1,904.50M 1,697.41M 4,340.30M 5,066.85M 4,675.23M
Total equity 6,366.50M 4,594.99M 853.25M 8,909.12M 10,930.18M
Operating cash flow -1,362.08M -1,826.62M -1,970.44M -4,027.34M -5,728.82M
 Jan 2016Jan 2017Jan 2018Jan 2019Jan 2020
Revenue 9.70M 8.75M 4.38M 6.72M 4.10M
Gross Profit -- 8.35M 3.90M -- --
Operating income -9.29M -17.82M -39.16M -33.85M -50.31M
Income before tax -9.68M -19.97M -35.23M -26.47M -47.28M
Net income -8.16M -16.92M -35.24M -26.48M -47.30M
EBITDA -9.17M -17.57M -38.68M -33.52M -49.94M
Diluted EPS -0.18 -0.37 -0.77 -0.54 -0.92
Dividends Per Share 0 0 0 -- 0
Total Assets 68.31M 55.89M 47.57M 128.42M 143.98M
Total liabilities 15.73M 15.07M 39.76M 46.55M 43.13M
Total equity 52.58M 40.81M 7.81M 81.86M 100.84M
Operating cash flow -11.25M -16.84M -17.62M -36.51M -52.53M

Valuation Measures

Jan 2020
PER--
ROA-34.87%
ROE-51.99%
Operating margin-1,226.68%
Profit margin-1,153.26%

Key executives

  • President, CEO & Representative Director: Keita Mori
  • Executive Officer & Manager-Operations: Hiroshi Yamamoto
  • Chief Medical Officer & Executive Officer: Bijan Nejadnik
  • Chief Technical Operations Officer: Chris sanbio Horan
  • Senior Managing Director & Executive Officer: Akihiro Tsujimura

Shareholders

  • KAWANISHI TORU (23.5%)
  • MORI KEITA (11.5%)
  • Sumitomo Dainippon Pharma Co., Ltd. (5.4%)
  • Teijin Ltd. (1.9%)
  • SASAKI KEIICHI /SHIBUYA/ (1.2%)
  • Nomura Asset Management Co., Ltd. (0.7%)
  • Matthews International Capital Management LLC (0.7%)
  • Vital KSK Holdings, Inc. (0.6%)
  • BlackRock Fund Advisors (0.5%)
  • Sawakami Asset Management, Inc. (0.2%)

Contact Details

  • Website:http://www.sanbio.com
  • Address: St. Luke Tower, 32/F, 8-1 Akaishi-cho, Tokyo, 104-0044, Japan
  • Phone: +81.3.6264.3481

Related Companies

  • SanBio, Inc.

Competitors

  • Neuren Pharmaceuticals Limited
  • Athersys, Inc.
  • Pluristem Therapeutics Inc.
Last Updated on 28 Sep, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media